ATE179169T1 - Prostaglandinanaloge - Google Patents

Prostaglandinanaloge

Info

Publication number
ATE179169T1
ATE179169T1 AT94111337T AT94111337T ATE179169T1 AT E179169 T1 ATE179169 T1 AT E179169T1 AT 94111337 T AT94111337 T AT 94111337T AT 94111337 T AT94111337 T AT 94111337T AT E179169 T1 ATE179169 T1 AT E179169T1
Authority
AT
Austria
Prior art keywords
prostaglandin analogues
prostaglandin
analogues
chem
preparation
Prior art date
Application number
AT94111337T
Other languages
English (en)
Inventor
Yutaka Mizushima
Toshihide C O Seikagak Inomata
-Chome Nihonbashi-Honcho
Arata Yasuda
Original Assignee
Yutaka Mizushima
Asahi Glass Co Ltd
Seikagaku Kogyo Co Ltd
Yoshitomi Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yutaka Mizushima, Asahi Glass Co Ltd, Seikagaku Kogyo Co Ltd, Yoshitomi Pharmaceutical filed Critical Yutaka Mizushima
Application granted granted Critical
Publication of ATE179169T1 publication Critical patent/ATE179169T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
AT94111337T 1989-10-16 1990-10-15 Prostaglandinanaloge ATE179169T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1266230A JP2602964B2 (ja) 1989-10-16 1989-10-16 プロスタグランジン類縁体およびその脂肪乳剤

Publications (1)

Publication Number Publication Date
ATE179169T1 true ATE179169T1 (de) 1999-05-15

Family

ID=17428079

Family Applications (2)

Application Number Title Priority Date Filing Date
AT90119772T ATE117989T1 (de) 1989-10-16 1990-10-15 Prostaglandinanaloge enthaltende lipidemulsion.
AT94111337T ATE179169T1 (de) 1989-10-16 1990-10-15 Prostaglandinanaloge

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT90119772T ATE117989T1 (de) 1989-10-16 1990-10-15 Prostaglandinanaloge enthaltende lipidemulsion.

Country Status (10)

Country Link
US (1) US5120870A (de)
EP (2) EP0624574B1 (de)
JP (1) JP2602964B2 (de)
AT (2) ATE117989T1 (de)
AU (1) AU641436B2 (de)
CA (1) CA2027351C (de)
DE (2) DE69016567T2 (de)
DK (2) DK0423697T3 (de)
ES (2) ES2132279T3 (de)
GR (2) GR3015963T3 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100243992B1 (ko) * 1994-01-18 2000-02-01 야스이 쇼사꾸 7-티아프로스타글란딘류 및 그 제조방법
KR20010023360A (ko) * 1997-08-27 2001-03-26 미즈시마 유타카 혈관신생 촉진제
US6632958B1 (en) 1998-06-04 2003-10-14 Mitsubishi Pharma Corporation Process for producing a purified prostaglandin derivative
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
JP2003342196A (ja) * 2002-05-31 2003-12-03 Mukku:Kk 静脈注射用組成物、その製造法およびその製剤
EP1711163A2 (de) * 2004-02-05 2006-10-18 Baxter International Inc. Unter verwendung von selbststabilisierenden mitteln hergestellte dispersionen
CA2586074C (en) * 2004-11-09 2013-07-23 Novagali Pharma Sa Ophthalmic oil-in-water type emulsion with stable positive zeta potential
ES2314354T3 (es) 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
DE602006016628D1 (de) * 2005-10-10 2010-10-14 Novagali Pharma Sa Prostaglandine enthaltende ophthalmische emulsionen
RU2470644C2 (ru) 2006-09-05 2012-12-27 Кью.Пи. КОПЭРЕЙШН Стабильная жировая эмульсия (варианты), способ ее получения, эмульгирующий агент и способы стабилизации простагландина и капель жира
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
EP2228058A1 (de) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
EP2389939A1 (de) 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4363817A (en) * 1981-08-27 1982-12-14 Miles Laboratories, Inc. Enol acylate analogs of E1 and E2 prostaglandins
JPS58222014A (ja) * 1982-06-18 1983-12-23 Taisho Pharmaceut Co Ltd プロスタグランジンｅ↓１脂肪乳剤
JPS59216820A (ja) * 1983-05-20 1984-12-06 Taisho Pharmaceut Co Ltd プロスタグランジン脂肪乳剤
JPH0818989B2 (ja) * 1984-01-12 1996-02-28 株式会社ミドリ十字 脂肪乳剤中のプロスタグランジンの安定化方法
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
JPS61151126A (ja) * 1984-12-25 1986-07-09 Teijin Ltd △７―プロスタグランジンａ１類を有効成分として含有する注射用の脂肪乳剤

Also Published As

Publication number Publication date
ES2132279T3 (es) 1999-08-16
GR3015963T3 (en) 1995-07-31
AU6452690A (en) 1991-04-18
DE69033069D1 (de) 1999-05-27
DE69016567D1 (de) 1995-03-16
AU641436B2 (en) 1993-09-23
DK0423697T3 (da) 1995-05-29
CA2027351C (en) 2001-06-19
EP0624574A3 (de) 1995-01-18
EP0423697B1 (de) 1995-02-01
JP2602964B2 (ja) 1997-04-23
EP0423697A2 (de) 1991-04-24
DK0624574T3 (da) 1999-10-25
GR3030718T3 (en) 1999-11-30
EP0624574A2 (de) 1994-11-17
US5120870A (en) 1992-06-09
ES2070238T3 (es) 1995-06-01
ATE117989T1 (de) 1995-02-15
EP0423697A3 (en) 1992-08-05
CA2027351A1 (en) 1991-04-17
DE69016567T2 (de) 1995-09-21
JPH03204853A (ja) 1991-09-06
DE69033069T2 (de) 1999-08-19
EP0624574B1 (de) 1999-04-21

Similar Documents

Publication Publication Date Title
ATE179169T1 (de) Prostaglandinanaloge
FI914905A (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten merkaptoasetyyliamidopyrrolo- ja -pyridobentsatsepiinijohdannaisten valmistamiseksi
FI95469C (fi) Analogiamenetelmä uusien hypoglykeemisten oksatsolidiinidionien valmistamiseksi
ES2054732T3 (es) Un procedimiento para preparar un derivado peptidico.
ES2058176T3 (es) Un procedimiento para preparar un derivado peptidico.
NO894349L (no) Tienopyridin-type mevalonolaktoner.
FI892222A0 (fi) Peptidalkoholer med antikoagulantverkan.
FI901277A0 (fi) 2,5,6,7-tetranor-4,8-inter-m-fenylen pg1z-derivativ.
DK377687A (da) Triazol-fungicidpraeparater
ATE60779T1 (de) N-glykolylneuraminsaeurederivat.
ES2089176T3 (es) Procedimiento para la preparacion de carboditioatos de piperidina fluorometil-sustituidos.
GR3006806T3 (de)
PT92668A (pt) Processo para a preparacao de derivados de azabiciclo-heptano
DK535388A (da) Anvendelse af piperidinopropiophenonforbindelse til fremstilling af et hypotensivt middel
DE58909745D1 (de) Tetrahydro-4-phenylimino-3-thiophenessigsäuren
DE58909563D1 (de) 3-Anilino-2-hydroxycarbonyl-4-thiophenessigsäuren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee